BioLineRx (NASDAQ:BLRX) Now Covered by StockNews.com

StockNews.com began coverage on shares of BioLineRx (NASDAQ:BLRX) in a report published on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

BioLineRx Trading Down 4.4 %

NASDAQ BLRX opened at $0.41 on Thursday. The stock has a market cap of $32.78 million, a P/E ratio of -0.91 and a beta of 1.46. The company has a current ratio of 1.61, a quick ratio of 1.49 and a debt-to-equity ratio of 1.34. BioLineRx has a 12-month low of $0.39 and a 12-month high of $1.93. The company has a fifty day simple moving average of $0.56 and a two-hundred day simple moving average of $0.64.

BioLineRx (NASDAQ:BLRX) last issued its earnings results on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. The firm had revenue of $5.39 million during the quarter, compared to analysts’ expectations of $3.93 million. On average, analysts forecast that BioLineRx will post -0.25 earnings per share for the current year.

Institutional Investors Weigh In On BioLineRx

An institutional investor recently bought a new position in BioLineRx stock. PVG Asset Management Corp acquired a new stake in shares of BioLineRx Ltd. (NASDAQ:BLRX) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 123,580 shares of the biotechnology company’s stock, valued at approximately $70,000. PVG Asset Management Corp owned 0.15% of BioLineRx at the end of the most recent quarter. 1.56% of the stock is owned by hedge funds and other institutional investors.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.